CD274 and neoplasm: Several markers including PD-L1 expression, lymphocytic infiltrates, tumor mutational burden (TMB), and mismatch repair deficiency (MMRd) appear to be helpful in predicting response to immune checkpoint inhibitors in specific tumor types [2].